Safety and efficacy of repeat ivermectin mass drug administrations for malaria control (RIMDAMAL II): a phase 3, double-blind, placebo-controlled, cluster-randomised, parallel-group trial.
Somé AF, Somé A, Sougué E, Ouédraogo COW, Da O, Dah SR, Nikièma F, Magalhaes T, Gray LI, Finical W, Pugh G, Lado P, Randall JC, Burton TA, Ring ME, Leon AS, Colt M, Li F, Wang K, Wade M, Lier AJ, Richards K, Sproch H, Zhang E, Ellman J, Achebe I, Jackson CL, Xiao M, Wu EJ, Bousema T, Slater HC, Foy BD, Parikh S, Dabiré RK.
Somé AF, et al. Among authors: colt m.
Lancet Infect Dis. 2025 Jul;25(7):737-750. doi: 10.1016/S1473-3099(24)00751-5. Epub 2025 Feb 4.
Lancet Infect Dis. 2025.
PMID: 39919778
Clinical Trial.